REG - GlaxoSmithKline PLC - Director/PDMR Shareholding
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.0080
956
£14.0080
769
£14.0080
640
d)
Aggregated information
2,365
Aggregated volume Price
£14.0080
e)
Date of the transaction
2021-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr I Mackay
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.0080
519
£14.0080
443
d)
Aggregated information
962
Aggregated volume Price
£14.0080
e)
Date of the transaction
2021-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr H Barron
b)
Position/status
Chief Scientific Officer and President, R&D
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 October 2021 on ADSs held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$38.6600
557
$38.6600
437
$38.6600
331
d)
Aggregated information
1,325
Aggregated volume Price
$38.6600
e)
Date of the transaction
2021-10-11
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Connor
b)
Position/status
President, Vaccines & Global Health
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.0080
250
£14.0080
242
£14.0080
140
d)
Aggregated information
632
Aggregated volume Price
£14.0080
e)
Date of the transaction
2021-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms D Conrad
b)
Position/status
SVP Human Resources
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.0080
100
£14.0080
92
d)
Aggregated information
192
Aggregated volume Price
£14.0080
e)
Date of the transaction
2021-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr J Ford
b)
Position/status
Senior Vice President and General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.0080
142
£14.0080
111
d)
Aggregated information
253
Aggregated volume Price
£14.0080
e)
Date of the transaction
2021-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr J Ford
b)
Position/status
Senior Vice President and General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 October 2021 on ADSs held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$38.6600
47
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2021-10-11
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms S Jackson
b)
Position/status
SVP, Global Communications & CEO Office
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.0080
60
£14.0080
56
d)
Aggregated information
116
Aggregated volume Price
£14.0080
e)
Date of the transaction
2021-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, GSK Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 October 2021 on ADSs held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$38.6600
93
$38.6600
80
$38.6600
101
d)
Aggregated information
274
Aggregated volume Price
$38.6600
e)
Date of the transaction
2021-10-11
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Miels
b)
Position/status
Chief Commercial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.0080
266
£14.0080
232
£14.0080
173
d)
Aggregated information
671
Aggregated volume Price
£14.0080
e)
Date of the transaction
2021-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.0080
237
£14.0080
170
£14.0080
136
d)
Aggregated information
543
Aggregated volume Price
£14.0080
e)
Date of the transaction
2021-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Simard
b)
Position/status
President, Pharmaceuticals Supply Chain
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.0080
85
£14.0080
120
£14.0080
102
d)
Aggregated information
307
Aggregated volume Price
£14.0080
e)
Date of the transaction
2021-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms K Terrell
b)
Position/status
Chief Digital & Technology Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 October 2021 on ADSs held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$38.6600
118
$38.6600
81
$38.6600
63
d)
Aggregated information
262
Aggregated volume Price
$38.6600
e)
Date of the transaction
2021-10-11
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.0080
138
£14.0080
98
£14.0080
79
d)
Aggregated information
315
Aggregated volume Price
£14.0080
e)
Date of the transaction
2021-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms D Waterhouse
b)
Position/status
Chief Executive Officer of ViiV Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.0080
163
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2021-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHEZLFFFBLXFBB
Recent news on GSK
See all newsREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - GSK submits Arexvy for adults 18+ with EMA
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG-GSK Plc: Director/PDMR Shareholding
Announcement